Intelligence » Pancreatitis » Last Year

Subscribe to get latest posts via email or subscribe to a RSS feed.

Sunday, July 16, 2017 -- Johns Hopkins Medicine surgeons have developed a minimally invasive surgery to address chronic pancreatitis, a painful condition that can be remedied by removing the pancreas. While some cases of chronic pancreatitis are caused by alcoholism, most of them are from a genetic mutation. But the suffers...

Wednesday, October 25, 2017 -- AzurRx BioPharma is planning to expand the clinical development of its investigative therapy MS1819 for the treatment of exocrine pancreatic insufficiency (EPI) caused by chronic inflammation of the pancreas and cystic fibrosis (CF) into Europe. The company has submitted an Investigational Medicinal Product Dossier (IMPD) — similar to an Investigational New Drug (IND) application in […] The post AzurRx Seeks to Expand Trial of MS1819 for EPI Caused by CF, Chronic Pancreatitis to Europe appeared first on Cystic Fibrosis News Today.

Tuesday, January 16, 2018 -- Some patients diagnosed with HP or AP have a significantly increased risk of developing pancreatic cancer.

Wednesday, May 17, 2017 -- Limited evidence suggests that early enteral feeding for patients hospitalized with mild-to-moderate acute pancreatitis may reduce length of hospital stay and gastrointestinal symptoms, compared with delayed feeding, according to data published in Annals of Internal Medicine.“Acute pancreatitis is among the most common and costly reasons for hospitalization in the United States,” Valerie M. Vaughn, MD, MSc, from Michigan Medicine and VA Ann Arbor Health System, and colleagues wrote.

Wednesday, September 20, 2017 -- OBJECTIVE Diabetes frequently develops in patients with chronic pancreatitis. We examined the alterations in the glucagon response to hypoglycemia and to oral glucose administration in patients with diabetes due to chronic pancreatitis. RESEARCH DESIGN AND METHODS Ten patients with diabetes secondary to chronic pancreatitis were compared with 13 patients with type 2 diabetes and 10 healthy control subjects. A stepwise hypoglycemic clamp and an oral glucose tolerance test (OGTT) were performed. RESULTS Glucose levels during the OGTT were higher in patients with diabetes and chronic pancreatitis and lower in control subjects (P < 0.0001). Insulin and C-peptide levels were reduced, and the glucose-induced suppression of glucagon was impaired in both groups with diabetes (all P < 0.0001 vs. control

Wednesday, June 21, 2017 -- OBJECTIVE To describe amylase/lipase activity levels and events of acute pancreatitis (AP) in the SCALE (Satiety and Clinical Adiposity—Liraglutide Evidence in individuals with and without diabetes) weight-management trials. RESEARCH DESIGN AND METHODS Secondary analyses were performed on pooled data from four trials (N = 5,358 with BMI ≥30, or 27 to <30 kg/m2 with ≥1 comorbidity). Of these, 1,723 had normoglycemia, 2,789 had prediabetes, and 846 had type 2 diabetes. Participants were randomized to liraglutide 3.0 mg (n = 3,302), liraglutide 1.8 mg (n = 211, only type 2 diabetes), or placebo (n = 1,845). Relationships between baseline characteristics and amylase/lipase activity at baseline and during treatment were investigated. RESULTS Over 56 weeks, liraglutide 3.0 mg versus placebo was

Wednesday, June 21, 2017 -- OBJECTIVE To evaluate serum amylase and lipase levels and the rate of acute pancreatitis in patients with type 2 diabetes and high cardiovascular risk randomized to liraglutide or placebo and observed for 3.5–5.0 years. RESEARCH DESIGN AND METHODS A total of 9,340 patients with type 2 diabetes were randomized to either liraglutide or placebo (median observation time 3.84 years). Fasting serum lipase and amylase were monitored. Acute pancreatitis was adjudicated in a blinded manner. RESULTS Compared with the placebo group, liraglutide-treated patients had increases in serum lipase and amylase of 28.0% and 7.0%, respectively. Levels were increased at 6 months and then remained stable. During the study, 18 (0.4% [1.1 events/1,000 patient-years of observation] [PYO]) liraglutide-treated and 23 (0.5%

Wednesday, September 20, 2017 -- Many patients with chronic pancreatitis develop diabetes (chronic pancreatitis–related diabetes [CPRD]) through an undetermined mechanism. Here we used long-term partial pancreatic duct ligation (PDL) as a model to study CPRD. We found that long-term PDL induced significant β-cell dedifferentiation, followed by a time-dependent decrease in functional β-cell mass—all specifically in the ligated tail portion of the pancreas (PDL-tail). High levels of transforming growth factor β1 (TGFβ1) were detected in the PDL-tail and were mainly produced by M2 macrophages at the early stage and by activated myofibroblasts at the later stage. Loss of β-cell mass was then found to result from TGFβ1-triggered epithelial-mesenchymal transition (EMT) by β-cells, rather than resulting directly from β-cell apoptosis. Mechanistically, TGFβ1-treated β-cells activated expression of

Monday, October 02, 2017 -- Pancreatitis remains a diagnostic challenge in patients with mild to moderate disease, with current imaging modalities being inadequate. Given the prominent macrophage infiltration in chronic pancreatitis, we hypothesized that 125I-iodo-DPA-713, a small-molecule radiotracer that specifically targets macrophages, could be used with SPECT/CT to image pancreatic inflammation in a relevant experimental model. Methods: Chronic pancreatitis was induced with cerulein in C57BL/6 mice, which were contrasted with saline-injected control mice. The animals were imaged at 7 wk after induction using N,N-diethyl-2-(2-(3-125I-iodo-4-methoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide (125I-iodo-DPA-713) SPECT/CT or 18F-FDG PET/CT. The biodistribution of 125I-iodo-DPA-713 was determined under the same conditions, and a pair of mice was imaged using a fluorescent analog of 125I-iodo-DPA-713, DPA-713-IRDye800CW, for correlative histology. Results: Pancreatic 125I-iodo-DPA-713 uptake was significantly higher in

Monday, June 12, 2017 -- by Shih-Yi Lin, Wu-Huei Hsu, Cheng-Chieh Lin, Cheng-Li Lin, Chung-Hao Tsai, Chia-Hung Kao Purpose Chronic exocrine pancreatic insufficiency can lead to osteoporosis. However, the incidence and risk of osteoporosis after acute inflammation of pancreas remained known. Thus, we conducted a population-based cohort study to clarify the association between acute pancreatitis (AP) and osteoporosis. Methods Patients newly diagnosed with AP with index date between 2000 and 2011 were identified from the National Health Insurance Research Database. Osteoporosis were defined according to the International Classification of Diseases, Ninth Revision, Clinical Modification codes. We applied age-, sex-, and comorbidities-adjusted variable Cox proportional hazard models for assessing the association between AP and osteoporosis. Moreover, these models were used to adjust for the influences

Wednesday, November 22, 2017 -- by Masaki Miyazawa, Hajime Takatori, Tetsuro Shimakami, Kazunori Kawaguchi, Kazuya Kitamura, Kuniaki Arai, Koichiro Matsuda, Taku Sanada, Takeshi Urabe, Katsuhisa Inamura, Takashi Kagaya, Hideki Mizuno, Uichiro Fuchizaki, Taro Yamashita, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Masao Honda, Shuichi Kaneko Background and aim Relapse and diabetes mellitus (DM) are major problems for the prognosis of autoimmune pancreatitis (AIP). We examined the prognosis of type 1 AIP after corticosteroid therapy (CST)-induced remission in terms of relapse and DM. Methods The study enrolled 82 patients diagnosed with type 1 AIP who achieved remission with CST. We retrospectively evaluated the relapse rate in terms of the administration period of CST, clinical factors associated with relapse, and the temporal change in glucose tolerance. Results

Monday, November 20, 2017 -- Radiology, Volume 285, Issue 3, Page 1061-1063, December 2017.

Thursday, May 18, 2017 -- The pancreas is an organ in the body that produces enzymes that help with digestion and regulate how the body processes sugar. It is found in the abdomen, tucked behind the stomach, and is long and flat in appearance. Much … The post Pancreatitis patients benefit from going against convention: Study appeared first on Bel Marra Health - Breaking Health News and Health Information.

Thursday, January 04, 2018 -- Use of epidural analgesia in patients with critically acute pancreatitis may reduce the 30-day mortality rates compared with the absence of a pain management strategy.

Wednesday, August 23, 2017 -- Results on First Six Patients Expected in September Company Adds Additional Clinical Trial Site to Further Support Enrollment in this Study and Other Planned Future Studies BROOKLYN, N.Y., Aug. 23, 2017 -- AzurRx...

Monday, August 14, 2017 -- Furosemide-induced acute pancreatitis can occur several hours to up to 7 weeks after starting treatment; dose may also play a role. This patient, the authors note, fell into the category of "long-term latency" and "low-dosage (40mg)"

Wednesday, June 14, 2017 -- Liraglutide does not increase the risk for acute pancreatitis in patients with type 2 diabetes who are also at high risk for cardiovascular events.

Tuesday, May 30, 2017 -- The FDA has issued fast-track designation to CM4620, a calcium release-activated calcium channel inhibitor for the treatment of acute pancreatitis, for which there are currently no approved therapies, the manufacturer announced.CM4620 (CalciMedica) “inhibits the uncontrolled increase in intracellular calcium in pancreatic acinar cells, preventing inappropriate digestive enzyme activation, acinar cell dysfunction and death, or necrosis,” according to a press release. The agent also “inhibits the Icrac pathway in human T cells, blocking the release of pro-inflammatory cytokines like IL-2 and IL-17, and has been shown to reduce neutrophil activation.”

Tuesday, May 16, 2017 -- When the excruciating pain of a pancreas attack sends someone to the hospital, eating is probably the last thing they're thinking of. And for decades, medical teams have kept such patients away from solid food for days.

Monday, September 04, 2017 -- Furosemide-induced acute pancreatitis can occur several hours to up to 7 weeks after starting treatment.

Related pages

where to buy turpentine oiloflox 400 tabletofloxuniphyllinnexito 5 purposecosaminealphanate package insertsandoz malaysiasleep medicine centers of wnyvitamin b50 reviewssmuth ointment compositioncaladryl usessandoz tobramycinvalprol cr 300 side effectsamisulpride bnfbacitracin polymyxinseptilin benefitswhere can i buy glacial acetic aciddolonex tabletlevocetirizine 2hclmebo creamcip zoxneurobion coated tablets merck kgaaoxeticaine in urduside effects of salbutamol inhalerorciprenaline doseparadine tabletअनवांटेड किट का उपयोगmedicated throat lozengesemifenac 50 dtzithromax capsuletab urimax 0.4 mgdha medicineketazol creamprorichsulfacetamide side effectscolodiumazelaic cream reviewscystone tabletsoflox 400 tabletmodafillupi hcgtriphasil 28phenobarbitone syrup gardenalecoderm creamuses for desonide creamparsley usesdeflazacort tablets usescapsule slimmingrevocon side effectsglenmate lotionbenzoic acid side effectsbetadine compositionsandoz clarithromycininduced pluerupotent stem cell in hindidaktacort cream reviewslipoic acid side effectsrtu latest updatescinitapridebenefits of verbenasinarisinaside effects of aczone geltranmedostoporinantilipemic tea side effectsflumelfebuget 40 useszincovit apex uses hindichloramine tablet fluponazurilcelastrus paniculataarixtra injectionvertin 24 side effects